|
Investigations
|
Units
|
Reference range
|
Number with abnormal results
|
Range of abnormal results
|
Mean/median
|
|---|
|
Thrombin time
|
Ratio
|
(0.86–1.14)
|
1
|
1.19
|
N/A
|
|
Classic APCR
|
Ratio
|
(3.3–5.82)
|
3
|
2.22, 2.25, 2.44
|
2.30/2.25
|
|
Modified APCR
|
Ratio
|
(2.63–3.34)
|
3
|
1.81,2.51, 2.53
|
2.28/2.51
|
|
Antithrombin activity
|
IU/dL
|
(85.9–117.5)
|
9
|
24.2–80.0
|
61.8/67.4
|
|
Protein C activity
|
IU/dL
|
(77.1–126.4)
|
9
|
38.5–72.5
|
58.3/61.5
|
|
Free protein S antigen
|
IU/dL
|
(80.2–137.4)
|
5
|
48.9–76.2
|
67.7/70.4
|
|
Lupus anticoagulant by dRVVT and dAPTT
|
-
|
Not detected
|
5
|
5 × positive
|
N/A
|
|
IgG aCL
|
GPL U/mL
|
(0–10)
|
3
|
11.2, 13.5, 17.2
|
14.0/13.5
|
|
IgM aCL
|
MPL U/mL
|
(0–10)
|
3
|
19.2, 19.7, 31.9
|
23.6/19.7
|
|
IgG aβ2GPI
|
SGU
|
(0–2.9)
|
3
|
3.9, 6.0, 8.6
|
6.2/6.0
|
|
IgM aβ2GPI
|
SMU
|
(0–6.5)
|
7
|
6.8–31.9
|
15.0/12.0
|
|
Homocysteine
|
µmol/L
|
(0–15)
|
5
|
15.2–18.0
|
16.1/15.6
|
|
VWF:GPIbR
|
IU/dL
|
(41–127)
|
4
|
380.1–494.1
|
426.0/415.0
|
|
VWF:Ag
|
IU/dL
|
(50–172)
|
11
|
280.8–682.7
|
531.3/581.3
|
|
FVIII:C
|
IU/dL
|
(50–150)
|
11
|
199.4–614.4
|
418.4/432.6
|
|
Thrombin:antithrombin complexes (TAT)
|
µg/L
|
(1–4.1)
|
7
|
9.22–74.6
|
24.3/25.1
|
|
Prothrombin fragment 1.2
|
pmol/L
|
(69–229)
|
3
|
333.3, 401.1, 964.0
|
566.1/401.1
|
|
Prothrombin 20,210
|
–
|
–
|
1
|
1 × heterozygous
|
N/A
|
|
Factor V Leiden
|
–
|
–
|
0
|
–
|
–
|
- aβ2GPI anti-β2 glycoprotein I antibodies, aCL anticardiolipin antibodies, APCR activated protein C resistance, dAPTT dilute activated partial thromboplastin time, dRVVT dilute Russell’s viper venom time, FVIII:C factor VIII coagulant activity assay, VWF:GPIbR ristocetin-triggered von Willebrand factor glycoprotein Ib-binding activity assay, VWF:Ag von Willebrand factor antigen
